InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | Altman Peter | Director & President and CEO | Purchase | 5,000 | $1.11 | $6K | 280.8K | View ↗ | |
| 2026-04-21 | Altman Peter | Director & President and CEO | Purchase | 400 | $1.23 | $492.00 | 275.8K | View ↗ | |
| 2026-04-20 | Altman Peter | Director & President and CEO | Purchase | 600 | $1.23 | $738.00 | 275.4K | View ↗ | |
| 2026-03-25 | Altman Peter | Director & President and CEO | Purchase | 300 | $1.22 | $366.00 | 274.8K | View ↗ | |
| 2026-03-24 | Altman Peter | Director & President and CEO | Purchase | 600 | $1.24 | $744.00 | 274.5K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Collaboration agreement revenue | $0-100.0% | $58K-87.8% | $477K | — |
| Research and development | $5.0M+13.1% | $4.4M-43.2% | $7.7M-12.5% | $8.8M |
| Selling, general and administrative | $3.3M-9.7% | $3.7M-16.5% | $4.4M-0.5% | $4.4M |
| Total costs and expenses | $8.3M+2.7% | $8.1M-33.5% | $12.1M-8.5% | $13.3M |
| Operating loss | -$8.3M-3.5% | -$8.0M+31.3% | -$11.6M+2.2% | -$11.9M |
| Total other income, net | $50K-9.1% | $55K | — | — |
| Net loss | -$8.2M-3.5% | -$7.9M+31.3% | -$11.6M+2.8% | -$11.9M |
| Net loss per share, basic and diluted (in dollars per share) | -$1K+57.6% | -$3K+64.6% | -$8K-1122.4% | -$670 |
| Weighted-average shares used in computing net loss per share, basic and diluted (in shares) | $6.67B+143.0% | $2.74B+94.3% | $1.41B-92.0% | $17.72B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures
BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure
BioCardia, Inc. Q4 2025 Earnings Call Summary